REGENERON PHARMACEUTICALS, INC. Earnings Per Share (Diluted)
REGENERON PHARMACEUTICALS, INC. (REGN) reported Earnings Per Share (Diluted) of $12.23 per share for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-07-30.
Financial Statements › Income Statement › Earnings Per Share
us-gaap:EarningsPerShareDiluted · last filed 2026-07-30
- REGENERON PHARMACEUTICALS, INC. earnings per share, diluted for the quarter ending 2026-06-30 was $12.23, a 4.53% decline year-over-year.
- REGENERON PHARMACEUTICALS, INC. earnings per share, diluted for the quarter ending 2026-03-31 was $6.75, a 7.15% decline year-over-year.
- REGENERON PHARMACEUTICALS, INC. earnings per share, diluted for the quarter ending 2025-09-30 was $13.62, a 18.02% increase year-over-year.
- REGENERON PHARMACEUTICALS, INC. earnings per share, diluted for the quarter ending 2025-06-30 was $12.81, a 3.22% increase year-over-year.
- REGENERON PHARMACEUTICALS, INC. earnings per share, diluted for fiscal 2025 was $41.48, a 8.19% increase from fiscal 2024.
- REGENERON PHARMACEUTICALS, INC. earnings per share, diluted for fiscal 2024 was $38.34, a 10.27% increase from fiscal 2023.
- REGENERON PHARMACEUTICALS, INC. earnings per share, diluted for fiscal 2023 was $34.77, a 9.03% decline from fiscal 2022.
- REGENERON PHARMACEUTICALS, INC. earnings per share, diluted for fiscal 2022 was $38.22, a 46.89% decline from fiscal 2021.
| Period end | Earnings Per Share, Diluted 3 month | Earnings Per Share, Diluted 3 month as first filed | Earnings Per Share, Diluted 6 month | Earnings Per Share, Diluted 6 month as first filed | Earnings Per Share, Diluted 9 month | Earnings Per Share, Diluted 9 month as first filed | Earnings Per Share, Diluted 12 month | Earnings Per Share, Diluted 12 month as first filed |
|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | $12.23 10-Q · filed 2026-07-30 | $18.95 10-Q · filed 2026-07-30 | ||||||
| 2026-03-31 | $6.75 10-Q · filed 2026-04-29 | |||||||
| 2025-12-31 | $41.48 10-K · filed 2026-02-04 | |||||||
| 2025-09-30 | $13.62 10-Q · filed 2025-10-28 | $33.61 10-Q · filed 2025-10-28 | ||||||
| 2025-06-30 | $12.81 10-Q · filed 2026-07-30 | $20.02 10-Q · filed 2026-07-30 | ||||||
| 2025-03-31 | $7.27 10-Q · filed 2026-04-29 | |||||||
| 2024-12-31 | $38.34 10-K · filed 2026-02-04 | |||||||
| 2024-09-30 | $11.54 10-Q · filed 2025-10-28 | $30.23 10-Q · filed 2025-10-28 | ||||||
| 2024-06-30 | $12.41 10-Q · filed 2025-08-01 | $18.68 10-Q · filed 2025-08-01 | ||||||
| 2024-03-31 | $6.27 10-Q · filed 2025-04-29 | |||||||
| 2023-12-31 | $34.77 10-K · filed 2026-02-04 | |||||||
| 2023-09-30 | $8.89 10-Q · filed 2024-10-31 | $24.57 10-Q · filed 2024-10-31 | ||||||
| 2023-06-30 | $8.50 10-Q · filed 2024-08-01 | $15.68 10-Q · filed 2024-08-01 | ||||||
| 2023-03-31 | $7.17 10-Q · filed 2024-05-02 | |||||||
| 2022-12-31 | $38.22 10-K · filed 2025-02-05 | |||||||
| 2022-09-30 | $11.66 10-Q · filed 2023-11-02 | $27.73 10-Q · filed 2023-11-02 | ||||||
| 2022-06-30 | $7.47 10-Q · filed 2023-08-03 | $16.07 10-Q · filed 2023-08-03 | ||||||
| 2022-03-31 | $8.61 10-Q · filed 2023-05-04 | |||||||
| 2021-12-31 | $71.97 10-K · filed 2024-02-05 | |||||||
| 2021-09-30 | $14.33 10-Q · filed 2022-11-03 | $52.29 10-Q · filed 2022-11-03 | ||||||
| 2021-06-30 | $27.97 10-Q · filed 2022-08-03 | $38.07 10-Q · filed 2022-08-03 | ||||||
| 2021-03-31 | $10.09 10-Q · filed 2022-05-04 | |||||||
| 2020-12-31 | $10.24 10-K · filed 2021-02-08 | $30.52 10-K · filed 2023-02-06 | ||||||
| 2020-09-30 | $7.39 10-Q · filed 2021-11-04 | $20.36 10-Q · filed 2021-11-04 | ||||||
| 2020-06-30 | $7.61 10-Q · filed 2021-08-05 | $13.03 10-Q · filed 2021-08-05 | ||||||
| 2020-03-31 | $5.43 10-Q · filed 2021-05-06 | |||||||
| 2019-12-31 | $6.93 10-K · filed 2021-02-08 | $18.46 10-K · filed 2022-02-07 | ||||||
| 2019-09-30 | $5.86 10-K · filed 2021-02-08 | $11.54 10-Q · filed 2020-11-05 | ||||||
| 2019-06-30 | $1.68 10-K · filed 2021-02-08 | $5.69 10-Q · filed 2020-08-05 | ||||||
| 2019-03-31 | $3.99 10-K · filed 2021-02-08 | |||||||
| 2018-12-31 | $7.15 10-K · filed 2020-02-07 | $21.29 10-K · filed 2021-02-08 | ||||||
| 2018-09-30 | $5.17 10-K · filed 2020-02-07 | $14.14 10-Q · filed 2019-11-05 | ||||||
| 2018-06-30 | $4.82 10-K · filed 2020-02-07 | $8.97 10-Q · filed 2019-08-06 | ||||||
| 2018-03-31 | $4.16 10-K · filed 2020-02-07 | |||||||
| 2017-12-31 | $1.50 10-K · filed 2019-02-07 | $10.34 10-K · filed 2020-02-07 | ||||||
| 2017-09-30 | $3.32 10-K · filed 2019-02-07 | $6.66 derived: net income ÷ weighted average shares · filed 2018-11-06 | $8.84 10-Q · filed 2018-11-06 | |||||
| 2017-06-30 | $3.34 10-K · filed 2019-02-07 | $5.51 10-Q · filed 2018-08-02 | ||||||
| 2017-03-31 | $2.16 10-K · filed 2019-02-07 | |||||||
| 2016-12-31 | $2.19 10-K · filed 2018-02-08 | $7.70 10-K · filed 2019-02-07 | ||||||
| 2016-09-30 | $2.27 10-K · filed 2018-02-08 | $3.96 derived: net income ÷ weighted average shares · filed 2017-11-08 | $5.51 10-Q · filed 2017-11-08 | |||||
| 2016-06-30 | $1.69 10-K · filed 2018-02-08 | $3.24 10-Q · filed 2017-08-03 | ||||||
| 2016-03-31 | $1.59 10-K · filed 2018-02-08 | $1.45 10-Q · filed 2016-05-05 | ||||||
| 2015-12-31 | $1.34 10-K · filed 2017-02-09 | $5.52 10-K · filed 2018-02-08 | ||||||
| 2015-09-30 | $1.82 10-K · filed 2017-02-09 | $3.51 derived: net income ÷ weighted average shares · filed 2016-11-04 | $4.18 10-Q · filed 2016-11-04 | $5.15 derived: net income ÷ weighted average shares · filed 2017-02-09 | ||||
| 2015-06-30 | $1.69 10-K · filed 2017-02-09 | $2.35 10-Q · filed 2016-08-04 | $3.32 derived: net income ÷ weighted average shares · filed 2017-02-09 | $4.05 derived: net income ÷ weighted average shares · filed 2017-02-09 | ||||
| 2015-03-31 | $0.66 10-K · filed 2017-02-09 | $1.63 derived: net income ÷ weighted average shares · filed 2017-02-09 | $2.36 derived: net income ÷ weighted average shares · filed 2017-02-09 | |||||
| 2014-12-31 | $0.78 10-K · filed 2016-02-11 | $0.96 10-K · filed 2015-02-12 | $1.70 derived: net income ÷ weighted average shares · filed 2017-02-09 | $2.98 10-K · filed 2017-02-09 | $3.07 10-K · filed 2015-02-12 | |||
| 2014-09-30 | $0.73 10-K · filed 2016-02-11 | $0.70 10-Q · filed 2014-11-04 | $2.19 10-Q · filed 2015-11-04 | $2.10 10-Q · filed 2014-11-04 | ||||
| 2014-06-30 | $0.85 10-K · filed 2016-02-11 | $0.82 10-Q · filed 2014-08-05 | $1.46 10-Q · filed 2015-08-04 | $1.40 10-Q · filed 2014-08-05 | ||||
| 2014-03-31 | $0.61 10-K · filed 2016-02-11 | $0.58 10-Q · filed 2014-05-08 | ||||||
| 2013-12-31 | $0.86 10-K · filed 2015-02-12 | $2.13 derived: net income ÷ weighted average shares · filed 2016-02-11 | $3.72 10-K · filed 2016-02-11 | $3.81 10-K · filed 2014-02-13 | ||||
| 2013-09-30 | $1.25 10-K · filed 2015-02-12 | $2.95 10-Q · filed 2014-11-04 | ||||||
| 2013-06-30 | $0.79 10-K · filed 2015-02-12 | $1.69 10-Q · filed 2014-08-05 | ||||||
| 2013-03-31 | $0.90 10-K · filed 2015-02-12 | |||||||
| 2012-12-31 | $4.08 10-K · filed 2014-02-13 | $5.63 derived: net income ÷ weighted average shares · filed 2015-02-12 | $6.75 10-K · filed 2015-02-12 | |||||
| 2012-09-30 | $1.72 10-K · filed 2014-02-13 | $2.55 10-Q · filed 2013-11-05 | ||||||
| 2012-06-30 | $0.70 10-K · filed 2014-02-13 | $0.81 10-Q · filed 2013-08-06 | ||||||
| 2012-03-31 | $0.11 10-K · filed 2014-02-13 | |||||||
| 2011-12-31 | -$2.45 10-K · filed 2014-02-13 | |||||||
| 2011-09-30 | -$0.68 10-Q · filed 2012-10-24 | -$1.87 10-Q · filed 2012-10-24 | ||||||
| 2011-06-30 | -$0.69 10-Q · filed 2012-07-25 | -$1.18 10-Q · filed 2012-07-25 | ||||||
| 2011-03-31 | -$0.49 10-Q · filed 2012-04-26 | |||||||
| 2010-12-31 | -$1.26 10-K · filed 2013-02-15 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ALNYLAM PHARMACEUTICALS, INC. (ALNY) | United States | $33.420B | 54.94 |
| Zoetis Inc. (ZTS) | United States | $29.045B | 11.38 |
| INSMED Inc (INSM) | United States | $26.566B | -26.60 |
| Roivant Sciences Ltd. (ROIV) | $26.105B | -96.08 | |
| BRISTOL MYERS SQUIBB CO (BMY) | United States | $125.637B | 12.67 |
| Royalty Pharma plc (RPRX) | United States | $22.628B | |
| UNITED THERAPEUTICS Corp (UTHR) | United States | $20.249B | 17.64 |
| Viatris Inc (VTRS) | United States | $20.008B | -0.00 |
| VERTEX PHARMACEUTICALS INC / MA (VRTX) | United States | $132.481B | 28.56 |
| Jazz Pharmaceuticals plc (JAZZ) | $15.333B | 16.07 |